- Home
- CHRS vs OXSQ Comparison
CHRS vs OXSQ Comparison
Compare CHRS & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- OXSQ
- Stock Information
- Founded
- CHRS 2010
- OXSQ 2003
- Country
- CHRS United States
- OXSQ United States
- Employees
- CHRS N/A
- OXSQ N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- OXSQ Blank Checks
- Sector
- CHRS Health Care
- OXSQ Finance
- Exchange
- CHRS Nasdaq
- OXSQ Nasdaq
- Market Cap
- CHRS 84.2M
- OXSQ 164.9M
- IPO Year
- CHRS 2014
- OXSQ N/A
- Fundamental
- Price
- CHRS $0.82
- OXSQ $2.26
- Analyst Decision
- CHRS Buy
- OXSQ
- Analyst Count
- CHRS 3
- OXSQ 0
- Target Price
- CHRS $4.68
- OXSQ N/A
- AVG Volume (30 Days)
- CHRS 1.3M
- OXSQ 533.4K
- Earning Date
- CHRS 08-07-2025
- OXSQ 08-12-2025
- Dividend Yield
- CHRS N/A
- OXSQ 18.58%
- EPS Growth
- CHRS N/A
- OXSQ N/A
- EPS
- CHRS N/A
- OXSQ N/A
- Revenue
- CHRS $272,251,000.00
- OXSQ $42,166,831.00
- Revenue This Year
- CHRS N/A
- OXSQ N/A
- Revenue Next Year
- CHRS $106.56
- OXSQ N/A
- P/E Ratio
- CHRS $1.90
- OXSQ N/A
- Revenue Growth
- CHRS 19.87
- OXSQ N/A
- 52 Week Low
- CHRS $0.66
- OXSQ $2.14
- 52 Week High
- CHRS $2.43
- OXSQ $3.10
- Technical
- Relative Strength Index (RSI)
- CHRS 53.65
- OXSQ 45.27
- Support Level
- CHRS $0.72
- OXSQ $2.14
- Resistance Level
- CHRS $0.77
- OXSQ $2.33
- Average True Range (ATR)
- CHRS 0.04
- OXSQ 0.03
- MACD
- CHRS 0.01
- OXSQ 0.01
- Stochastic Oscillator
- CHRS 91.74
- OXSQ 66.67
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.